|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,137.50 JPY | -0.42% |
|
+0.85% | +2.13% |
| 06-30 | Trump's push for the world's lowest drug prices hits snag with mid-sized companies | RE |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| Market Cap | 3,829B 23.58B 20.63B 19.03B 17.59B 33.4B 2,249B 33.98B 226B 89.07B 1,108B 88.52B 86.61B | P/E 2027 * |
11.1x | P/E 2028 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3,753B 23.1B 20.21B 18.65B 17.24B 32.73B 2,203B 33.3B 222B 87.28B 1,086B 86.75B 84.87B | EV / Sales 2027 * |
1.67x | EV / Sales 2028 * | 1.66x |
| Free-Float |
97.66% | Yield 2027 * |
3.76% | Yield 2028 * | 3.87% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -0.42% | ||
| 1 week | +0.85% | ||
| Current month | -1.72% | ||
| 1 month | -0.54% | ||
| 3 months | -18.54% | ||
| 6 months | -3.41% | ||
| Current year | +2.13% |
| 1 week | 2,130 |  | 2,216.5 |
| 1 month | 2,041 | | 2,216.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,368 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 09/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 31/10/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 31/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 09/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 31/05/2019 |
| Director/Board Member | 58 | 31/05/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.42% | +0.85% | +56.59% | +3.71% | 23.64B | |
| +0.09% | +2.12% | +56.49% | +169.19% | 1,084B | |
| -1.63% | +2.02% | +66.31% | +62.70% | 634B | |
| -1.12% | -0.46% | +31.69% | +84.44% | 447B | |
| +0.18% | +2.04% | +30.19% | +26.51% | 330B | |
| -6.22% | -3.61% | +29.15% | +32.09% | 295B | |
| -1.27% | -0.56% | +27.21% | +46.39% | 285B | |
| -0.93% | -1.19% | -28.85% | -40.38% | 218B | |
| -1.19% | +0.63% | +22.43% | +66.30% | 199B | |
| -0.72% | +7.04% | +21.41% | +81.19% | 169B | |
| Average | -1.31% | +2.40% | +31.26% | +53.21% | 368.35B | |
| Weighted average by Cap. | -1.09% | +2.47% | +39.87% | +84.28% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,250B 13.85B 12.12B 11.18B 10.33B 19.63B 1,321B 19.97B 133B 52.34B 651B 52.02B 50.89B | 2,072B 12.76B 11.16B 10.29B 9.52B 18.07B 1,216B 18.38B 122B 48.19B 599B 47.89B 46.85B |
| Net income | 345B 2.12B 1.86B 1.71B 1.58B 3.01B 202B 3.06B 20.34B 8.02B 99.71B 7.97B 7.79B | 325B 2B 1.75B 1.61B 1.49B 2.83B 191B 2.88B 19.17B 7.55B 93.97B 7.51B 7.34B |
| Net Debt | -76.78B -473M -414M -382M -353M -670M -45.09B -681M -4.53B -1.79B -22.22B -1.77B -1.74B | -391B -2.41B -2.11B -1.94B -1.8B -3.41B -230B -3.47B -23.1B -9.1B -113B -9.04B -8.85B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/07/26 | JP¥2,137.50 | -0.42% | 4,773,500 |
| 08/07/26 | JP¥2,146.50 | -1.29% | 6,198,900 |
| 07/07/26 | JP¥2,174.50 | -1.52% | 6,880,100 |
| 06/07/26 | JP¥2,208.00 | +2.60% | 4,506,600 |
| 03/07/26 | JP¥2,152.00 | +0.58% | 5,173,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
